An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Lyra Therapeutics, a clinical-stage biotech company, has granted non-qualified stock options to new non-executive employees as inducement awards. The options allow the purchase of 78,400 shares of Lyra Therapeutics common stock, with a ten-year term and an exercise price of $4.72 per share. Vests over a four-year period, subject to continued service.
Lyra Therapeutics, un'azienda biotecnologica in fase clinica, ha concesso opzioni su azioni non qualificate a nuovi dipendenti non esecutivi come premi di incentivo. Le opzioni consentono l'acquisto di 78.400 azioni ordinarie di Lyra Therapeutics, con un termine di dieci anni e un prezzo di esercizio di $4,72 per azione. L'assegnazione delle opzioni avviene su un periodo di quattro anni, a condizione di continuare il servizio.
Lyra Therapeutics, una empresa biotecnológica en etapa clínica, ha otorgado opciones sobre acciones no calificadas a nuevos empleados no ejecutivos como premios de incentivo. Las opciones permiten la compra de 78,400 acciones comunes de Lyra Therapeutics, con un plazo de diez años y un precio de ejercicio de $4.72 por acción. Se acumulan durante un período de cuatro años, sujeto a la continuidad en el servicio.
임상 단계의 생명공학 회사인 Lyra Therapeutics는 새로운 비집행 직원들에게 유도 보상으로 비자격 주식 옵션을 부여하였습니다. 이 옵션은 10년의 기간 동안 Lyra Therapeutics의 보통주 78,400주를 주당 $4.72의 행사 가격으로 구매할 수 있습니다. 계속된 서비스를 조건으로 4년 동안에 걸쳐 할당됩니다.
Lyra Therapeutics, une entreprise biotechnologique en phase clinique, a accordé des options d'achat d'actions non qualifiées à de nouveaux employés non exécutifs comme primes d'incitation. Les options permettent l'achat de 78 400 actions ordinaires de Lyra Therapeutics, avec un terme de dix ans et un prix d'exercice de 4,72 $ par action. Elles sont acquises sur une période de quatre ans, sous réserve de la continuation du service.
Lyra Therapeutics, ein Biotechnologieunternehmen in der klinischen Phase, hat neuen nicht-exekutiven Mitarbeitern nicht qualifizierte Aktienoptionen als Anreizprämien gewährt. Die Optionen ermöglichen den Kauf von 78.400 Stammaktien von Lyra Therapeutics, mit einer Laufzeit von zehn Jahren und einem Ausübungspreis von $4,72 pro Aktie. Die Zuteilung erfolgt über einen Zeitraum von vier Jahren, vorausgesetzt, der Dienst wird fortgesetzt.
Positive
None.
Negative
None.
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of Lyra Therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with Lyra Therapeutics. The employment inducement awards were approved by Lyra’s independent directors serving on its Compensation Committee and granted under Lyra’s 2022 Employment Inducement Award Plan, as amended, and related form of stock option agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Lyra Therapeutics, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Lyra Therapeutics, pursuant to Nasdaq Listing Rule 5635(c)(4).
Each option carries a ten-year term and an exercise price per share equal to $4.72, which was the closing price of Lyra’s common stock on April 26, 2024, the date of grant, and vests over a four-year period as follows: 25% of the option vests on the one year anniversary of the applicable employee’s start date and an additional 1/48th of the option vests in equal monthly installments over the following three years, subject to the employee’s continued service through each vesting date.
About Lyra Therapeutics
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), a highly prevalent inflammatory disease of the paranasal sinuses which leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioabsorbable sinonasal implants designed to be administered in a simple, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy (7500µg MF) to the sinonasal passages. LYR-210 is designed for patients with narrow anatomy, primarily those who have not undergone ethmoid sinus surgery, and is being evaluated in the ENLIGHTEN Phase 3 clinical program, while LYR-220, an enlarged implant, was evaluated in the BEACON Phase 2 clinical trial in patients who have recurrent symptoms despite having had ethmoid sinus surgery. These two product candidates are designed to treat the estimated four million CRS patients in the United States who fail medical management each year. For more information, please visit www.lyratx.com and follow us on LinkedIn.
Contact Information:
Ellen Cavaleri, Investor Relations 615.618.6228 ecavaleri@lyratx.com
FAQ
How many shares of Lyra Therapeutics common stock were granted as inducement awards?
78,400 shares were granted to 16 new non-executive employees.
What is the exercise price per share for the stock options?
The exercise price per share is $4.72, based on the closing price of Lyra's common stock on April 26, 2024.
How long is the term of each option granted?
Each option carries a ten-year term.
How does the vesting schedule work for the stock options?
25% of the option vests on the one year anniversary of the employee's start date, with the remaining vesting in equal monthly installments over the following three years, contingent on continued service.
What is the purpose of the inducement awards granted by Lyra Therapeutics?
The awards were granted as an inducement for new non-executive employees to accept employment with the company.
Who approved the employment inducement awards at Lyra Therapeutics?
The awards were approved by Lyra's independent directors serving on its Compensation Committee.
Under what Nasdaq rule were the inducement awards granted?
The awards were granted under Nasdaq Listing Rule 5635(c)(4) for inducement purposes.
What is the purpose of Lyra's 2022 Employment Inducement Award Plan?
The plan is used exclusively for granting equity awards to new individuals joining or rejoining Lyra Therapeutics.
How are the stock options granted different from regular employee stock options?
The options are granted to individuals not previously employed by Lyra or after a period of non-employment, as an inducement to join the company.
How many independent directors approved the employment inducement awards?
The awards were approved by Lyra's independent directors serving on its Compensation Committee.
lyra therapeutics, inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. the company's xtreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. its product candidates include lyr-210 and lyr-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. the company was formerly known as 480 biomedical, inc. and changed its name to lyra therapeutics, inc. in july 2018. lyra therapeutics, inc. was founded in 2005 and is headquartered in watertown, massachusetts.
